FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer, a First Dual-Targeted Option After Chemo Fails
WASHINGTON — The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rybrevant Faspro, a subcutaneous dual-targeted therapy from Johnson & Johnson, for adults with advanced head and neck cancer whose disease has progressed after platinum-based chemotherapy and immunotherapy, the agency and the company announced on Thursday, November 5, 2026. The decision gives patients with recurrent or metastatic head and neck squamous cell carcinoma a new option in a setting where, according to Johnson & Johnson, there has been no new advance in second-line treatment for a decade. Rybrevant Faspro — known generically as amivantamab and hyaluronidase-lpuj — is the first dual-targeted therapy approved for this group of patients. It is given as a single agent by injection under the skin, and it works by targeting two proteins at once, EGFR and MET, both of which can help head and neck cancers grow and resist treatment. The approval was based on the OrigAMI-4 trial, in w...